Creso Pharma (ASX: CPH)
Following the Australian government’s announcement that medical cannabis has now been approved for sale in Australia, several ASX listed medical cannabis stocks are now on the front foot to reap what could be very lucrative rewards.
One ASX stock that hopes to lead the charge has signed a Letter of Intent with a local pharmaceutical group for the import and sale of cannabis products in the Australian market.
Importantly, this Australian pharma group has been granted a federal import license for medical cannabis – thus facilitating this ASX stock’s Australian market entry.
This ASX medical cannabis company is well on track to expand its Australian presence with a diverse range of products in various stages of readiness to hit retail stores, and quickly start generating revenues…
This growing medicinal cannabis company’s deal with an Aussie pharma company works favourably.
With authorisation of imported medical cannabis from international sources to boost domestic supply now in play, this ASX stock can meet Australian demand almost immediately, before domestic suppliers get in on the action.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
This ASX stock will be further boosted by the appointment of Swiss Professor Dr Felix Gutzwiller to its Scientific Advisory Board. Dr Gutzwiller has an enormous amount of political clout and experience dealing with changing regulatory environments and will be invaluable in the expansion of the company’s European operations.
So with a political mover and shaker on board, products ready for consumption and a favourable legislative landscape, this ASX company is moving quickly to take advantage of the multi-billion dollar medicinal cannabis and nutraceutical markets.